WO2002017912A1 - Antagonistes de l'endotheline - Google Patents

Antagonistes de l'endotheline Download PDF

Info

Publication number
WO2002017912A1
WO2002017912A1 PCT/US2001/027220 US0127220W WO0217912A1 WO 2002017912 A1 WO2002017912 A1 WO 2002017912A1 US 0127220 W US0127220 W US 0127220W WO 0217912 A1 WO0217912 A1 WO 0217912A1
Authority
WO
WIPO (PCT)
Prior art keywords
trans
benzodioxol
carboxylic acid
ethyl
pyrrohdine
Prior art date
Application number
PCT/US2001/027220
Other languages
English (en)
Inventor
Martin Winn
Steven A. Boyd
Charles W. Hutchins
Jae Hwan-Soo
Andrew S. Tasker
Tomas W. Von Geldern
Jeffrey Kester
Bryan K. Sorensen
Bruce G. Szczepankiewicz
Kenneth Henry
Gang Liu
Steven J. Wittenberger
Steven A. King
Todd J. Janus
Robert J. Padley
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/653,563 external-priority patent/US7208517B1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of WO2002017912A1 publication Critical patent/WO2002017912A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

L'invention concerne un composé correspondant à la formule (I), ou un sel pharmaceutiquement acceptable de ce composé, ainsi que des procédés et des intermédiaires pour la préparation de ce composé. L'invention concerne également un procédé pour lutter contre l'action de l'endothéline.
PCT/US2001/027220 2000-08-31 2001-08-31 Antagonistes de l'endotheline WO2002017912A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/653,563 US7208517B1 (en) 1994-08-19 2000-08-31 Endothelin antagonists
US09/653,563 2000-08-31

Publications (1)

Publication Number Publication Date
WO2002017912A1 true WO2002017912A1 (fr) 2002-03-07

Family

ID=24621388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027220 WO2002017912A1 (fr) 2000-08-31 2001-08-31 Antagonistes de l'endotheline

Country Status (1)

Country Link
WO (1) WO2002017912A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034085A1 (fr) * 2004-09-17 2006-03-30 Abbott Laboratories Forme cristalline de l’hydrochlorure d’atrasentan
WO2006034084A1 (fr) * 2004-09-17 2006-03-30 Abbott Laboratories Forme cristalline 2 de l’hydrochlorure d’atrasentan
WO2006034234A1 (fr) * 2004-09-17 2006-03-30 Abbott Laboratories Forme cristalline 3 de l’hydrochlorure d’atrasentan
WO2006034094A1 (fr) * 2004-09-17 2006-03-30 Abbott Laboratories Forme cristalline 1 de l’hydrochlorure d’atrasentan
WO2011114103A1 (fr) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones pour usage médicamenteux
US8569341B2 (en) 2010-06-04 2013-10-29 Amgen Inc. Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer
US8623819B2 (en) 2007-08-22 2014-01-07 AbbVie Deutschland GmbH & Co. KG Therapy for complications of diabetes
US8952036B2 (en) 2013-02-28 2015-02-10 Amgen Inc. Benzoic acid derivative MDM2 inhibitor for the treatment of cancer
US9376386B2 (en) 2013-06-10 2016-06-28 Amgen, Inc. Processes of making and crystalline forms of a MDM2 inhibitor
US9376425B2 (en) 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
CN105745204A (zh) * 2013-09-12 2016-07-06 艾伯维公司 用于治疗肾脏疾病的阿曲生坦扁桃酸盐
US9758495B2 (en) 2013-03-14 2017-09-12 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
WO2018010656A1 (fr) * 2016-07-12 2018-01-18 南京明德新药研发股份有限公司 Dérivé de pyrrolidine servant d'agoniste de ppar
US11396493B2 (en) 2017-12-21 2022-07-26 Guangdong Raynovent Biotech Co., Ltd. Amorphous pyrrolidine derivative as PPAR agonist and preparation method thereof
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006095A1 (fr) * 1994-08-19 1996-02-29 Abbott Laboratories Antagonistes d'endotheline
WO1997030046A1 (fr) * 1996-02-13 1997-08-21 Abbott Laboratories Derives d'acide 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylique utilises comme antagonistes de l'endotheline
WO1997030045A1 (fr) * 1996-02-13 1997-08-21 Abbott Laboratories Derives de pyrrolidine a substitution benzo-1,3-dioxolyl et benzofuranyl servant d'antagonistes de l'endotheline

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006095A1 (fr) * 1994-08-19 1996-02-29 Abbott Laboratories Antagonistes d'endotheline
WO1997030046A1 (fr) * 1996-02-13 1997-08-21 Abbott Laboratories Derives d'acide 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylique utilises comme antagonistes de l'endotheline
WO1997030045A1 (fr) * 1996-02-13 1997-08-21 Abbott Laboratories Derives de pyrrolidine a substitution benzo-1,3-dioxolyl et benzofuranyl servant d'antagonistes de l'endotheline

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU, GANG ET AL: "Design, Synthesis, and Activity of a Series of Pyrrolidine-3- carboxylic Acid-Based, Highly Specific, Orally Active ETB Antagonists Containing a Diphenylmethylamine Acetamide Side Chain", J. MED. CHEM. (1999), 42(18), 3679-3689, XP002187525 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051301B2 (en) 2004-09-17 2015-06-09 Abbvie Inc. Crystalline form of a drug
WO2006034084A1 (fr) * 2004-09-17 2006-03-30 Abbott Laboratories Forme cristalline 2 de l’hydrochlorure d’atrasentan
WO2006034234A1 (fr) * 2004-09-17 2006-03-30 Abbott Laboratories Forme cristalline 3 de l’hydrochlorure d’atrasentan
WO2006034094A1 (fr) * 2004-09-17 2006-03-30 Abbott Laboratories Forme cristalline 1 de l’hydrochlorure d’atrasentan
JP2008513481A (ja) * 2004-09-17 2008-05-01 アボット・ラボラトリーズ アトラセンタン塩酸塩の結晶形２
WO2006034085A1 (fr) * 2004-09-17 2006-03-30 Abbott Laboratories Forme cristalline de l’hydrochlorure d’atrasentan
US8865650B2 (en) 2007-08-22 2014-10-21 AbbVie Deutschland GmbH & Co. KG Therapy for complications of diabetes
US8623819B2 (en) 2007-08-22 2014-01-07 AbbVie Deutschland GmbH & Co. KG Therapy for complications of diabetes
US9592231B2 (en) 2007-08-22 2017-03-14 AbbVie Deutschland GmbH & Co. KG Therapy for complications of diabetes
WO2011114103A1 (fr) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones pour usage médicamenteux
US8569341B2 (en) 2010-06-04 2013-10-29 Amgen Inc. Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer
US9296736B2 (en) 2010-06-04 2016-03-29 Amgen Inc. Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer
US9593129B2 (en) 2010-06-04 2017-03-14 Amgen, Inc. Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer
US9376425B2 (en) 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
US8952036B2 (en) 2013-02-28 2015-02-10 Amgen Inc. Benzoic acid derivative MDM2 inhibitor for the treatment of cancer
US9758495B2 (en) 2013-03-14 2017-09-12 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
US9855259B2 (en) 2013-06-10 2018-01-02 Amgen Inc. Processes of making and crystalline forms of a MDM2 inhibitor
US9623018B2 (en) 2013-06-10 2017-04-18 Amgen Inc. Processes of making and crystalline forms of a MDM2 inhibitor
US9757367B2 (en) 2013-06-10 2017-09-12 Amgen Inc. Calcium propane-2-sulfinate dihydrate
US9801867B2 (en) 2013-06-10 2017-10-31 Amgen Inc. Processes of making and crystalline forms of a MDM2 inhibitor
US9376386B2 (en) 2013-06-10 2016-06-28 Amgen, Inc. Processes of making and crystalline forms of a MDM2 inhibitor
CN105745204A (zh) * 2013-09-12 2016-07-06 艾伯维公司 用于治疗肾脏疾病的阿曲生坦扁桃酸盐
WO2018010656A1 (fr) * 2016-07-12 2018-01-18 南京明德新药研发股份有限公司 Dérivé de pyrrolidine servant d'agoniste de ppar
CN109563032A (zh) * 2016-07-12 2019-04-02 广东众生睿创生物科技有限公司 作为ppar激动剂的吡咯烷衍生物
US10526320B2 (en) 2016-07-12 2020-01-07 Guangdong Raynovent Biotech Co., Ltd. Pyrrolidine derivatives as PPAR agonists
RU2711991C1 (ru) * 2016-07-12 2020-01-23 Гуандун Рейновент Биотек Ко., Лтд. Производные пирролидина в качестве агонистов ppar
CN109563032B (zh) * 2016-07-12 2022-05-20 广东众生睿创生物科技有限公司 作为ppar激动剂的吡咯烷衍生物
US11396493B2 (en) 2017-12-21 2022-07-26 Guangdong Raynovent Biotech Co., Ltd. Amorphous pyrrolidine derivative as PPAR agonist and preparation method thereof

Similar Documents

Publication Publication Date Title
US6462194B1 (en) Endothelin antagonists
JP3741441B2 (ja) エンドセリン・アンタゴニスト
EP0885215B1 (fr) Derives de pyrrolidine a substitution benzo-1,3-dioxolyl et benzofuranyl servant d'antagonistes de l'endotheline
US6946481B1 (en) Endothelin antagonists
WO1999006397A2 (fr) Antagonistes d'endotheline
WO2002017912A1 (fr) Antagonistes de l'endotheline
US7365093B2 (en) Endothelin antagonists
EP0888340A1 (fr) Derives d'acide 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylique utilises comme antagonistes de l'endotheline
WO1998057933A1 (fr) Derives d'acide carboxylique de pyrrolidine comme antagonistes d'endotheline
AU781355B2 (en) Novel benzo-1,3-dioxolyl-and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
AU2005201160B2 (en) Endothelin antagonists
AU725122B2 (en) Endothelin antagonists
NZ514170A (en) Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
CZ2000348A3 (cs) Deriváty pyrrolidin-3-karboxylové kyseliny a jejich použití jako antagonistů endothelinu
NZ514171A (en) Benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
EP0991620A1 (fr) Derives d'acide carboxylique de pyrrolidine comme antagonistes d'endotheline
AU2008201198A1 (en) Endothelin anatagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP